Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

ADCs have transformed bladder cancer treatment, but challenges like toxicity management and high costs remain significant hurdles. ADCs vary in components and mechanisms, influencing outcomes and ...

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...

SAN DIEGO, March 25, 2025 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work than the perfunctory punctuation suggests. That hyphen stands for the ...

The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...

Sidewinder Therapeutics has secured $137m in a Series B financing round to progress its pipeline of bispecific antibody-drug conjugates (ADCs) – marking the continued growth in investor interest over ...